Lexicon Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1995-01-01
- Employees
- 285
- Market Cap
- $621.7M
- Website
- http://www.lexpharma.com
- Introduction
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
Lexicon's SONATA-HCM Phase 3 Trial Design Unveiled at European Cardiology Congress
Lexicon Pharmaceuticals has launched SONATA-HCM, the only ongoing Phase 3 trial evaluating sotagliflozin in both obstructive and non-obstructive hypertrophic cardiomyopathy, with enrollment active across 20 countries.
Lexicon's Non-Opioid Pain Drug Pilavapadin Misses Primary Endpoint in Phase IIb Diabetic Neuropathy Trial
Lexicon Pharmaceuticals' non-opioid painkiller pilavapadin failed to achieve statistical significance versus placebo in Phase IIb RELIEF-DPN-1 trial for diabetic neuropathy pain.
Sotagliflozin Shows Breakthrough 23% Reduction in Heart Attack and Stroke Risk for Diabetic Kidney Disease Patients
A landmark clinical trial led by Mount Sinai researchers demonstrates that sotagliflozin, a dual SGLT1/2 inhibitor, reduces heart attacks, strokes, and cardiovascular deaths by 23% in patients with type 2 diabetes and chronic kidney disease.
Lexicon's LX9211 Shows Promise for Diabetic Neuropathic Pain, Sotagliflozin Demonstrates Cardiovascular Benefits
Lexicon Pharmaceuticals' LX9211, a non-opioid therapy, completed Phase 2b trial for diabetic peripheral neuropathic pain, exceeding enrollment targets due to high interest.
Lexicon to Host Expert Panel on LX9211, Novel Non-Opioid Treatment for Diabetic Neuropathic Pain
Lexicon Pharmaceuticals will host a virtual webcast on January 28, 2025, featuring an in-depth discussion of LX9211, their investigational non-opioid treatment for diabetic peripheral neuropathic pain.
FDA Gears Up for Year-End Decisions on Novel Therapies for Rare Diseases and Cancer
The FDA is set to decide on Ionis Pharmaceuticals' olezarsen for familial chylomicronemia syndrome (FCS), a rare genetic disease, by December 19, following positive Phase III results.
Lexicon Pharmaceuticals Completes Enrollment for Phase IIb Trial of LX9211 in Diabetic Peripheral Neuropathic Pain
Lexicon Pharmaceuticals has finished enrolling 494 subjects in its Phase IIb PROGRESS trial, exceeding the initial target by 20%, to evaluate LX9211 for diabetic peripheral neuropathic pain (DPNP).
Lexicon Pharmaceuticals Restructures, Cuts 60% of Staff After FDA Flags Zynquista Deficiencies
Lexicon Pharmaceuticals will lay off 60% of its workforce and disband its sales team to save $100 million, pivoting to focus on its research pipeline.
Lexicon's Sotagliflozin Faces Setback in Type 1 Diabetes Approval Bid After FDA Advisory Committee Vote
Lexicon Pharmaceuticals faces another hurdle for sotagliflozin as an FDA advisory committee votes against its approval for type 1 diabetes, despite prior EU approval.
FDA Panel Rejects Sotagliflozin for Type 1 Diabetes with Mild-to-Moderate CKD
An FDA advisory panel voted against approving sotagliflozin as an adjunct to insulin for type 1 diabetes patients with mild-to-moderate chronic kidney disease, citing concerns over the risk-benefit ratio.